Search clinical trials for: Nilotinib

Total 2980 results

Tianjin Medical University Cancer Institute and...

Recruiting

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC (SAINT)

Non Small Cell Lung Cancer

China
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (ALTER-L004)

Non Small Cell Lung Cancer

China
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Niguarda Hospital

Completed

Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Leukemia, Myeloid, Chronic-Phase

Italy
Novartis Pharmaceuticals

Terminated

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Switzerland, United States, Germany, Singapore, Korea, Republic of, Canada
XSpray Microparticles

Completed

Pharmacokinetic Comparison of XS003 and Tasigna

Healthy

United Kingdom
Georgetown University

Unknown

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease (PD Nilotinib)

Parkinson Disease | Parkinsons Disease With Dementia

United States
KeifeRx, LLC
Worldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries...

Not yet recruiting

Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)

Alzheimer Disease
Novartis Pharmaceuticals

No longer available

MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia (ALL)
Novartis Pharmaceuticals

Completed

Bioavailability Study Comparing Two New Nilotinib Tablet Formulations to an Established Nilotinib Capsule Formulation in Healthy Volunteers

Healthy
Sheba Medical Center

Completed

Nilotinib Pre and Post Allogeneic Stem Cell Transplantation

Stem Cell Transplantation | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

Israel
Samsung Medical Center

Completed

Study of Nilotinib in Metastatic Melanoma With KIT Aberrations

Metastatic Melanoma With KIT Aberration

Korea, Republic of
Shenzhen Second People's Hospital
Dongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The... and other collaborators

Recruiting

Nilotinib for First-line Newly Diagnosed CML-CP Patients

Chronic Myeloid Leukemia, Chronic Phase | Nilotinib

China
Andrew J. Wagner, MD, PhD
Massachusetts General Hospital; Novartis; Brigham and Women's Hospital

Active, not recruiting

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Tenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis | Diffuse-type Giant Cell Tumor

United States
Novartis Pharmaceuticals

No longer available

MAP to Provide Access to Nilotinib, for Patients With HES

Hypereosinophilic Syndrome (HES)
University Health Network, Toronto
Novartis

Terminated

A Study of Nilotinib in Growing Vestibular Schwannomas

Growing Vestibular Schwannomas

Canada
Novartis Pharmaceuticals

Completed

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib (MACS1428)

Chronic Myelogenous Leukemia in Chronic Phase

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. (NILOMEL)

Stage IV Melanoma | Stage III Melanoma | Amplification | Malignant Skin Melanoma T0

France
Seoul St. Mary's Hospital
Novartis

Unknown

Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib (AMICAN)

Chronic Myeloid Leukemia

Korea, Republic of
National Taiwan University Hospital

Completed

Nilotinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation

Patients Who Have Received Allo-HSCT

Taiwan
Georgetown University

Completed

Nilotinib in Cognitively Impaired Parkinson Disease Patients 001

Parkinson's Disease | Parkinson's Disease Dementia | Diffuse Lewy Body Disease

United States
Novartis Pharmaceuticals

Completed

An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment (MACS0999)

Chronic Myelogenous Leukemia

United States, Canada
Jill M Kolesar
National Cancer Institute (NCI); Novartis

Recruiting

Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Metastatic Melanoma | BRAF Gene Mutation

United States
Novartis Pharmaceuticals

Completed

Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line (NOFRETETE)

Chronic Myeloid Leukemia

Germany
Hospital for Special Surgery, New York
Novartis Pharmaceuticals; Rudolph Rupert Scleroderma Program

Completed

Nilotinib in the Treatment of Systemic Sclerosis

Systemic Sclerosis

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

Healthy

United States
Novartis Pharmaceuticals

Completed

Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. (NILOdeepR)

Chronic Myeloid Leukemia

Germany
Novartis Pharmaceuticals

Completed

A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. (ENESTPath)

Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Germany, Belgium, France, Italy, Spain, Hungary, Austria, Sweden, Bulgaria, Denmark, Greece, Slovenia, United Kingdom, Czechia, Romania, Serbia, Slovakia, Portugal, Finland, Norway, Poland
Seoul National University Hospital
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Nilotinib in CML-CP (ENESTKorea)

Chronic Myeloid Leukemia, Chronic Phase
Indiana University
Novartis

Completed

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Neurofibromatosis | NF1 | Neurofibromas

United States
Gruppo Italiano Trapianto di Midollo Osseo

Completed

Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD (Nilo-cGVHD)

Chronic Graft Versus Host Disease

Israel, Italy
Georgetown University

Unknown

Nilotinib in Huntington's Disease (Tasigna HD)

Huntington Disease

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Completed

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Melanoma | Acral Melanoma | Mucosal Lentiginous Melanoma

United States
Weill Medical College of Cornell University
Novartis Pharmaceuticals

Completed

Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy

Chronic Myeloid Leukemia

United States
Novartis Pharmaceuticals

Completed

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Chronic Myelogenous Leukemia

Turkey
Stanford University
Novartis

Completed

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Lymphoma, Non-Hodgkin | Lymphoma, T-Cell, Peripheral | Bone Marrow Transplant Failure

United States, Canada
Rony Schaffel

Terminated

Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALLPhi)

Acute Lymphoblastic Leukemia | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
M.D. Anderson Cancer Center
Novartis

Withdrawn

Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Cancer
China Medical University, China
General Hospital of Shenyang Military Region; Shengjing Hospital; Liaoning Tumor... and other collaborators

Unknown

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Non Small Cell Lung Cancer
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Jiangnan University; Chia Tai Tianqing Pharmaceutical... and other collaborators

Unknown

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Non-Small-Cell Lung

China
Hangzhou Cancer Hospital

Unknown

RT Plus EGFR-TKI for Wild-type NSCLC

Non-small Cell Lung Cancer | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)

China
M.D. Anderson Cancer Center
Novartis

Completed

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

Leukemia, Myelogenous, Chronic

United States
Shanghai University of Traditional Chinese Medicine
Shanghai Chest Hospital; Shanghai Pulmonary Hospital, Shanghai, China

Completed

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

Cancer
Peking Union Medical College Hospital

Recruiting

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Pheochromocytoma | Paraganglioma

China
Peking Union Medical College Hospital

Recruiting

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Paraganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, Malignant

China
Novartis Pharmaceuticals

Active, not recruiting

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (ENESTfreedom)

Chronic Myelogenous Leukemia

Belgium, Spain, Austria, Germany, Italy, France, Netherlands, Sweden, Japan, United States, Greece, United Kingdom, Bulgaria, Hungary, Argentina, Poland, Colombia, Ireland, Denmark
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
First Hospital of Shijiazhuang City

Unknown

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

Carcinoma | Small Cell Lung Cancer | Lung Neoplasm

China
David Piccioni, M.D., Ph.D
Novartis

Completed

Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas

Glioma

United States

Search clinical trials for: Nilotinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations